Skip to main content

Zerit XR Side Effects

Generic name: stavudine

Medically reviewed by Drugs.com. Last updated on Jun 26, 2023.

Note: This document contains side effect information about stavudine. Some dosage forms listed on this page may not apply to the brand name Zerit XR.

Applies to stavudine: oral capsule.

Warning

Oral route (Capsule; Powder for Solution)

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported. Fatal lactic acidosis has been reported in pregnant individuals who received the combination of stavudine and didanosine with other antiretroviral agents. Coadministration of stavudine and didanosine is contraindicated because of increased risk of serious and/or life-threatening events. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur. Fatal and nonfatal pancreatitis have occurred during therapy when stavudine was part of a combination regimen that included didanosine.

Serious side effects of Zerit XR

Along with its needed effects, stavudine (the active ingredient contained in Zerit XR) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking stavudine:

More common

Incidence not known

Other side effects of Zerit XR

Some side effects of stavudine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to stavudine: oral capsule, oral capsule extended release, oral powder for reconstitution.

General

This drug was associated with many side effects (e.g., polyneuropathy, lactic acidosis, lipoatrophy) for which mitochondrial toxicity was a potential underlying mechanism.[Ref]

Hepatic

Very common (10% or more): Elevated bilirubin (up to 68%), elevated ALT (up to 65%), elevated AST (up to 63%), elevated GGT (up to 28%), elevated hepatic transaminases (up to 13%)

Uncommon (0.1% to 1%): Hepatitis/jaundice

Frequency not reported: Severe hepatomegaly with steatosis, fatal hepatic events, hepatosplenomegaly

Postmarketing reports: Hepatic steatosis, hepatitis, liver failure, hepatotoxicity resulting in death[Ref]

In a monotherapy trial, elevated ALT (greater than 5 times the upper limit of normal [5 x ULN]), AST (greater than 5 x ULN), and bilirubin (greater than 2.5 x ULN) were reported in 13%, 11%, and 2% of patients, respectively. Elevated ALT (up to 5 x ULN) and AST (up to 5 x ULN) were reported in 65% and 63% of patients, respectively.

In combination therapy trials, elevated AST (grades 3 to 4: up to 7%; all grades: up to 53%), ALT (grades 3 to 4: up to 8%; all grades: up to 50%), bilirubin (grades 3 to 4: up to 16%; all grades: up to 68%), and GGT (grades 3 to 4: up to 5%; all grades: up to 28%) were reported; grades 3 to 4 AST, ALT, and GGT elevations were greater than 5 x ULN and grades 3 to 4 bilirubin elevations were greater than 2.6 x ULN.

In clinical trials, modest elevations of hepatic transaminases not requiring dose adjustment were reported in up to 13% of patients.

Hepatosplenomegaly (up to 72%) was reported in children; this side effect was not listed for adults.

Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs alone or in combination, including this drug and other antiretroviral agents.

Fatal hepatic events were reported most often in patients treated with this drug in combination with hydroxyurea and didanosine.[Ref]

Nervous system

Very common (10% or more): Headache (up to 54%), peripheral neurologic symptoms/neuropathy (up to 52%), peripheral neuropathy (up to 24%), dizziness (up to 11%)

Common (1% to 10%): Paresthesia, peripheral neuritis, somnolence

Frequency not reported: Peripheral sensory neuropathy, ototoxicity, syncope, encephalopathy, abnormal gait, tremor, hyperkinesia, speech disorder, ear disorder, ear pain, otitis media

Postmarketing reports: Motor weakness (including severe cases)[Ref]

In clinical trials, peripheral neuropathy requiring or leading to dose adjustment (regardless of severity) was reported in up to 24% of patients. Other peripheral neurological symptoms not requiring dose changes were reported in up to 39% of patients. Neuropathy requiring dose adjustment was reported in up to 14% of patients.

Peripheral sensory neuropathy (generally characterized by numbness, tingling, or pain in the feet or hands) has been reported. Peripheral neuropathy (some cases severe) was dose-related and occurred more often in patients with advanced HIV disease, with history of peripheral neuropathy, or using other drugs associated with neuropathy. Symptoms generally resolved after dose reduction or interruption of this drug.

Syncope (up to 15%), encephalopathy (up to 17%), abnormal gait (up to 11%), tremor (up to 11%), hyperkinesia (up to 10%), ear disorder (up to 39%), ear pain (up to 45%), otitis media (up to 15%), and speech disorder (up to 10%) were reported in children; these side effects were not listed for adults.

Most cases of motor weakness occurred in the setting of symptomatic hyperlactatemia or lactic acidosis syndrome. Symptoms have continued or worsened after therapy was stopped.[Ref]

Gastrointestinal

In a monotherapy trial, elevated amylase (at least 1.4 x ULN) was reported in 14% of patients.

In combination therapy trials, elevated amylase (grades 3 to 4: up to 8%; all grades: up to 31%) and lipase (grades 3 to 4: up to 6%; all grades: up to 26%) were reported; grades 3 to 4 amylase and lipase elevations were greater than 2 x ULN.

Ulcerative stomatitis (up to 45%), melena (up to 11%), tooth caries (up to 11%), dysphagia (up to 15%), aphthous stomatitis (up to 10%), cheilitis (up to 10%), gastrointestinal disorder (up to 15%), and glossitis (up to 10%) were reported in children; these side effects were not listed for adults.

Abdominal pain, elevated lipase, and pancreatitis (including fatal cases) have also been reported during postmarketing experience.[Ref]

Very common (10% or more): Nausea (up to 53%), diarrhea (up to 50%), nausea/vomiting (up to 39%), abdominal pain (up to 34%), vomiting (up to 30%), elevated amylase (up to 31%), elevated lipase (up to 26%), dyspepsia (up to 12%)

Common (1% to 10%): Pancreatitis (including fatal cases), constipation

Frequency not reported: Ulcerative stomatitis, melena, tooth caries, dysphagia, aphthous stomatitis, cheilitis, gastrointestinal disorder, glossitis[Ref]

Other

Infection (up to 95%), accidental injury (up to 80%), AIDS (up to 22%), death (up to 17%), face edema (up to 25%), mucous membrane disorder (up to 11%), peripheral edema (up to 10%), and enlarged abdomen (up to 10%) were reported in children; these side effects were not listed for adults.

Edema has been reported with use of this drug although no causal relationship has been established.

Chills/fever have also been reported during postmarketing experience.[Ref]

Very common (10% or more): Chills/fever (up to 50%), asthenia (up to 35%), pain (up to 21%), malaise (up to 20%)

Common (1% to 10%): Fatigue

Frequency not reported: Edema, infection, accidental injury, AIDS, death, face edema, mucous membrane disorder, enlarged abdomen, peripheral edema

Antiretroviral therapy:

-Frequency not reported: Increased weight, increased blood lipid levels[Ref]

Dermatologic

Very common (10% or more): Rash (up to 40%), sweating (up to 18%), pruritus (up to 15%)

Common (1% to 10%): Maculopapular rash, lipoatrophy

Uncommon (0.1% to 1%): Urticaria

Frequency not reported: Subcutaneous fat loss, progressive subcutaneous fat wasting, ecchymosis, lesions, vesiculobullous rash, dry skin, skin discoloration, seborrhea, skin disorder, fungal dermatitis, nail disorder, petechial rash, skin ulcer, herpes zoster

Postmarketing reports: Lipodystrophy[Ref]

Subcutaneous fat loss was most apparent in the face, limbs, and buttocks. The incidence and severity of lipoatrophy have been linked to cumulative exposure. Often, lipoatrophy was not reversible when this drug was discontinued.

Ecchymosis (up to 30%), lesions (up to 55%), vesiculobullous rash (up to 25%), dry skin (up to 35%), skin discoloration (up to 20%), seborrhea (up to 11%), skin disorder (up to 15%), fungal dermatitis (up to 15%), nail disorder (up to 15%), petechial rash (up to 15%), skin ulcer (up to 10%), and herpes zoster (up to 15%) were reported in children; these side effects were not listed for adults.

Lipoatrophy has also been reported during postmarketing experience.[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (up to 32%), arthralgia (up to 23%), back pain (up to 19%)

Frequency not reported: Osteonecrosis, muscle weakness, decreased bone mineral density, arthrosis[Ref]

Arthrosis (up to 11%) was reported in children; this side effect was not listed for adults.

Myalgia has also been reported during postmarketing experience.[Ref]

Psychiatric

Very common (10% or more): Insomnia (up to 29%), depression (up to 24%), anxiety (up to 22%), nervousness (up to 12%)

Common (1% to 10%): Abnormal dreams, abnormal thinking

Uncommon (0.1% to 1%): Emotional lability

Frequency not reported: Personality disorder[Ref]

Personality disorder (up to 11%) was reported in children; this side effect was not listed for adults.

Insomnia has also been reported during postmarketing experience.[Ref]

Hematologic

In a monotherapy trial, decreased neutrophils (less than 750/mm3) and platelets (less than 50,000/mm3) were reported in 5% and 3% of patients, respectively.

Low hemoglobin (less than 8 g/dL) was reported in less than 1% of patients[Ref]

Very common (10% or more): Lymphadenopathy (up to 20%)

Common (1% to 10%): Decreased neutrophils, decreased platelets, low hemoglobin

Postmarketing reports: Anemia, leukopenia, neutropenia, macrocytosis, thrombocytopenia[Ref]

Metabolic

Very common (10% or more): Anorexia (up to 19%)

Common (1% to 10%): Asymptomatic hyperlactatemia

Uncommon (0.1% to 1%): Lactic acidosis (some cases involved motor weakness)

Frequency not reported: Hyperlipidemia, cachexia, dehydration

Postmarketing reports: Symptomatic hyperlactatemia, diabetes mellitus, hyperglycemia, redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")

Antiretroviral therapy:

-Frequency not reported: Increased glucose levels[Ref]

Cachexia (up to 15%) and dehydration (up to 10%) were reported in children; these side effects were not listed for adults.

Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs alone or in combination with other antiretrovirals. Fatal lactic acidosis has been reported in pregnant women who received this drug plus didanosine with other antiretroviral agents.

Anorexia and lactic acidosis have also been reported during postmarketing experience.[Ref]

Respiratory

Very common (10% or more): Influenza syndrome (up to 15%), dyspnea (up to 15%)

Frequency not reported: Cough, rhinitis, pharyngitis, respiratory disorder, lung disorder, asthma, epistaxis, hypoventilation, pneumonia, hyperventilation, voice alteration, sinusitis, stridor[Ref]

Cough (up to 95%), rhinitis (up to 100%), pharyngitis (up to 56%), respiratory disorder (up to 60%), lung disorder (up to 44%), asthma (up to 45%), epistaxis (up to 28%), hypoventilation (up to 22%), pneumonia (up to 22%), hyperventilation (up to 15%), voice alteration (up to 25%), sinusitis (up to 10%), and stridor (up to 20%) were reported in children; these side effects were not listed for adults.[Ref]

Cardiovascular

Very common (10% or more): Chest pain (up to 11%)

Frequency not reported: Tachycardia, vasodilation[Ref]

Tachycardia (up to 10%) and vasodilation (up to 15%) were reported in children; these side effects were not listed for adults.[Ref]

Hypersensitivity

Allergic reaction has also been reported during postmarketing experience.[Ref]

Common (1% to 10%): Allergic reactions[Ref]

Oncologic

Common (1% to 10%): Neoplasms, benign skin neoplasm[Ref]

Endocrine

Uncommon (0.1% to 1%): Gynecomastia[Ref]

Ocular

Frequency not reported: Conjunctivitis, eye disorder, abnormal vision, conjunctival edema[Ref]

Conjunctivitis (up to 44%), eye disorder (up to 17%), abnormal vision (up to 11%), and conjunctival edema (up to 20%) were reported in children; these side effects were not listed for adults.[Ref]

Genitourinary

Genital pain (up to 17%) and urinary incontinence (up to 11%) were reported in children; these side effects were not listed for adults.[Ref]

Frequency not reported: Genital pain, urinary incontinence[Ref]

Immunologic

Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)[Ref]

Renal

Frequency not reported: Fanconi syndrome[Ref]

References

1. Petersen E, Ramirez-Ronda C, Schwartz R, Peterson D, Hardy W, Sacks H, Follansbee S. Findings from a phase II study of stavudine (d4T). Int Conf AIDS. 1992;8:b90(ab.no.po3023).

2. Dunkle L, Anderson R, McLaren C, Cross A, Brown M, Gugliotti R, Adler M, Kaul S. Stavudine (d4T) a promising anti-retroviral agent. Int Conf AIDS. 1992;8:we47(ab.no.eb1011).

3. Brinkman K, terHofstede HJM, Burger DM, Smeitinkt JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-44.

4. Hurst M, Noble S. Stavudine - An update of its use in the treatment of HIV infection. Drugs. 1999;58:919-49.

5. Drugs for HIV infection. Med Lett Drugs Ther. 2001;43:103-8.

6. Walker UA, Bauerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology. 2004;39:311-7.

7. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22:685-708.

8. Neff GW, Sherman KE, Eghtesad B, Fung J. Review article: current status of liver transplantation in HIV-infected patients. Aliment Pharmacol Ther. 2004;20:993-1000.

9. Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy. 2006;26:1111-33.

10. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-43.

11. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis. 2007;44:453-5.

12. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis. 2007;45:254-60.

13. Currier JS. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis. 2007;45:261-2.

14. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS. 2007;21:2455-64.

15. Cerner Multum, Inc. Australian Product Information.

16. Nelson M, Azwa A, Sokwala A, Harania RS, Stebbing J. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS. 2008;22:1374-6.

17. Thoden J, Lebrecht D, Venhoff N, Neumann J, Muller K, Walker UA. Highly active antiretroviral HIV therapy-associated fatal lactic acidosis: quantitative and qualitative mitochondrial DNA lesions with mitochondrial dysfunction in multiple organs. AIDS. 2008;22:1093-4.

18. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf 2017.

19. Browne MJ, Mayer KH, Chafee SB, Dudley MN, Posner MR, Steinberg SM, Graham KK, Geletko SM, Zinner SH, Denman SL, et al. 2' related complex: a phase I trial. J Infect Dis. 1993;167:21-9.

20. Squires KE, Weiss W, Sacks H, Hassett J, Gugliotti R, Murray H. Effect of 2'3'-didehydro-3'deoxythymidine (d4T) on p24 antigenemia in patients with AIDS or ARC. Int Conf AIDS. 1990;6:180(ab.no.th..241).

21. Product Information. Zerit (stavudine). Bristol-Myers Squibb. 2001;PROD.

22. Schiano TD, Lissoos TW, Ahmed A, Siano C, Zaitman D, Cohn G, Ehrenpreis ED. Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis. Am J Gastroenterol. 1997;92:1563-4.

23. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: A report of five cases. Clin Infect Dis. 2000;30:198-200.

24. Johri S, Alkhuja S, Siviglia G, Soni A. Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy. Aids. 2000;14:1286-7.

25. Delgado J, Harris M, Tesiorowski A, Montaner JS. Symptomatic elevations of lactic Acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clin Infect Dis. 2001;33:2072-4.

26. Mandelbrot L, Kermarrec N, Marcollet A, et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS. 2003;17:272-3.

27. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005;19:585-592.

28. Cerner Multum, Inc. UK Summary of Product Characteristics.

29. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073-89.

30. McComsey GA, Re VL 3rd, O'Riordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis. 2008;46:1290-6.

31. Drugs for HIV infection. Treat Guidel Med Lett. 2009;7:11-22.

32. Shalit P, Farrell P, Lindgren P. Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting. Aids. 2001;15:804-5.

33. Rey D, L'Heritier A, Lang JM. Severe Ototoxicity in a Health Care Worker Who Received Postexposure Prophylaxis with Stavudine, Lamivudine, and Nevirapine after Occupational Exposure to HIV. Clin Infect Dis. 2002;34:418-9.

34. Warnke D, Barreto J, Temesgen Z. Antiretroviral drugs. J Clin Pharmacol. 2007;47:1570-9.

35. Callens S, De Schacht C, Huyst V, Colebunders R. Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment. J Infect. 2003;47:188-9.

36. SaintMarc T, Partisani M, PoizotMartin I, Bruno F, Rouviere O, Lang JM, Gastaut JA, Touraine JL. A syndrome of peripheral fat wasting (Lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-67.

37. SaintMarc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS. 1999;13:2188-9.

38. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. Aids. 2000;14:1309-16.

39. Martinez E, Mocroft A, GarciaViejo MA, PerezCuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A, Gatell. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-8.

40. Manfredi R, Calza L, Chiodo F. Gynecomastia associated with highly antiretroviral therapy. Ann Pharmacother. 2001;35:438-9.

41. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-98.

42. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr. 2006;166:13-21.

43. Anti-HIV agents. New drugs, new hope, old lessons. TreatmentUpdate. 2007;19:1-3.

44. Brambilla AM, Novati R, Calori G, et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS. 2003;17:1993-5.

45. Bergersen BM. Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy. Drugs. 2006;66:1971-87.

46. Ter Hofstede HJ, Koopmans PP, Burger DM. Stavudine plasma concentrations and lipoatrophy. J Antimicrob Chemother. 2008;61:933-8.

47. Guyot S, Hayoz D, Telenti A, Cavassini M. Peripheral oedema and high arterial blood flow as a complication of antiretroviral therapy. AIDS. 2004;18:356-8.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer